SCHEMBL3489500

SCHEMBL3489500

O=C1N(Cc2ccccc2)c2cc(Cl)cc(Cl)c2S(=O)(=O)N1Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.47
CA12 O43570 3/20 0.47
CA9 Q16790 3/20 0.47
CA1 P00915 1/20 0.47
CASP1 P29466 1/20 0.44
CASP3 P42574 1/20 0.44
CASP4 P49662 1/20 0.44
CASP7 P55210 1/20 0.44
CASP9 P55211 1/20 0.44
CASP6 P55212 1/20 0.44
CASP8 Q14790 1/20 0.44
APP P05067 4/20 0.41
MAPT P10636 4/20 0.41
SNCA P37840 4/20 0.41
LMNA P02545 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GFER P55789 1/20 0.40
POLB P06746 1/20 0.40
CA2 P00918 1/20 0.40
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490199 0.92 CA12 (0.50) RAB9ACA12CA9CASP1CASP3
SCHEMBL3489133 0.89 F2 (0.42) CA12CA9CA1MAPTLMNA
SCHEMBL3489294 0.88 CA12 (0.43) CA12CA9CA1MAPTLMNA
SCHEMBL3490183 0.86 CA12 (0.45) RAB9ACA12CA9CASP1CASP3
SCHEMBL3489541 0.86 RAB9A (0.42) RAB9ACA12CA9CA1CASP1
SCHEMBL3489209 0.85 MAPT (0.38) CA12CA9CA1MAPTLMNA
SCHEMBL3489625 0.85 CA12 (0.43) CA12CA9CA1MAPTALDH1A1
SCHEMBL3491531 0.85 CA12 (0.43) CA12CA9CA1CASP3MAPT
SCHEMBL3490594 0.85 MAPT (0.47) CA12CA9MAPTLMNAALDH1A1
SCHEMBL3489640 0.84 MAPT (0.50) CASP6MAPTLMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D RAB9A 2919/4885CA12 4883/4885CA9 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.